Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis

dc.contributor.authorTuncer, Turkan
dc.contributor.authorKaya, Arzu
dc.contributor.authorGulkesen, Arif
dc.contributor.authorKal, Gul Ayden
dc.contributor.authorKaman, Dilara
dc.contributor.authorAkgol, Gurkan
dc.date.accessioned2026-08-12T17:18:01Z
dc.date.issued2019
dc.departmentFırat Üniversitesi
dc.description.abstractBackground. Rheumatoid arthritis (RA) is a chronic inflammatory and systemic disease of unknown etiology that primarily affects synovial joints and involves progressive destruction around the joints. Inflammation starting in the joint synovium causes the destruction of cartilage, bone and other adjacent tissues with pannus formation. Objectives. The aim of this study was to evaluate serum matrix metalloproteinase-3 (MMP-3) levels and their clinical and radiological significance in patients with rheumatoid arthritis. Material and methods. The study included 59 patients with RA and 30 healthy controls. Serum MMP-3 levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Patients with a Disease Activity Score 28 (DAS28) <= 3.2 were categorized as having lower disease activity, while a DAS28 score > 3.2 indicated patients with moderate/high disease activity. Additionally, the patients were divided into 2 groups in terms of disease duration: early RA (disease duration <= 2 years) and established RA (disease duration <= 2 years). Functional disability was evaluated using the Health Assessment Questionnaire (HAQ) and Nottingham Health Profile (NHP). Radiographs were scored using modified Larsen scoring. Results. Serum MMP-3 levels in patients with RA were significantly higher than in controls (p = 0.001). Serum MMP-3 levels were correlated with laboratory and clinical parameters of disease activity, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), DAS28, and HAQ score; the exceptions were rheumatoid factor (RF) and cyclic citrullinated peptides (CCP). The serum MMP-3 levels of RA patients with moderate/high disease activity were found to be significantly higher than those of the patients with low disease activity (p < 0.001). However, MMP-3 levels were found to be similar in both established and early RA patients (p = 0.927). Additionally, the modified Larsen scores, which indicate structural damage, correlated significantly with serum MMP-3 levels (p = 0.001). Conclusions. These results indicate that serum MMP-3 levels may be used as an indicator for structural damage such as erosions in the early stages of the disease, and to monitor disease activity.
dc.description.sponsorshipFirat University Scientific Research Projects Coordination Department, Elazig, Turkey
dc.description.sponsorshipFinancial support for the study was provided by the Firat University Scientific Research Projects Coordination Department, Elazig, Turkey.
dc.identifier.doi10.17219/acem/94065
dc.identifier.endpage670
dc.identifier.issn1899-5276
dc.identifier.issn2451-2680
dc.identifier.issue5
dc.identifier.orcid0000-0001-8085-7562
dc.identifier.pmid30740946
dc.identifier.scopus2-s2.0-85067189723
dc.identifier.scopusqualityQ1
dc.identifier.startpage665
dc.identifier.urihttps://doi.org/10.17219/acem/94065
dc.identifier.urihttps://hdl.handle.net/11508/52884
dc.identifier.volume28
dc.identifier.wosWOS:000469774300013
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWroclaw Medical Univ
dc.relation.ispartofAdvances in Clinical and Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectrheumatoid arthritis
dc.subjectmatrix metalloproteinase 3
dc.subjectdisease activity
dc.subjectmodified Larsen score
dc.titleMatrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis
dc.typeArticle

Dosyalar